China Biotech Services Holdings Limited
Simbols: 8037.HK
HKSE
0.305
HKDTirgus cena šodien
-2.3428
P/E koeficients
0.0000
PEG koeficients
293.79M
MRK Cap
- 0.03%
DIV ienesīgums
China Biotech Services Holdings Limited (8037-HK) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 206.9 | 92.8 | 152.3 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | -128.6 | 1.8 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 39.2 | 768.5 | 117.6 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 9.3 | 18.7 | 4.7 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 5.8 | 4.8 | 3.1 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 261.2 | 884.8 | 277.8 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 124.2 | 128.9 | 105.5 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 107.2 | 110.1 | 120.6 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 69.8 | 67.3 | 80.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 177 | 177.4 | 201.5 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 56.9 | 227.7 | 120.3 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 57.6 | -227.7 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | -14.6 | 279.5 | 1.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 401.2 | 585.7 | 429 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 0 | 662.4 | 1470.5 | 706.8 | ||||||||||||||||||
balance-sheet.row.account-payables | 0 | 5.8 | 206.4 | 16.1 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 94.7 | 16.6 | 63.6 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 3.7 | 242 | 85.2 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5.7 | 65.2 | 3.6 | ||||||||||||||||||
Deferred Revenue Non Current | 0 | -5.7 | 0 | -9.9 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 58.6 | 325.2 | 23.7 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 12.2 | 95.3 | 13.5 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 5.7 | 20.3 | 11.1 | ||||||||||||||||||
balance-sheet.row.total-liab | 0 | 171.6 | 644 | 240.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0 | 96.3 | 96.3 | 96.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -310.8 | -209.9 | -475.1 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 186.5 | 225.6 | 283.5 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 490.7 | 490.7 | 490.7 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 462.8 | 602.7 | 395.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 662.4 | 1470.5 | 706.8 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 28 | 223.8 | 70.5 | ||||||||||||||||||
balance-sheet.row.total-equity | 0 | 490.7 | 826.5 | 465.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||
Total Investments | 0 | 56.9 | 99.2 | 122 | ||||||||||||||||||
balance-sheet.row.total-debt | 0 | 100.4 | 81.8 | 67.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 0 | -106.5 | -11 | -83.4 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -95.4 | 862.8 | 180.7 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 55.6 | 66.4 | 68.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 381.7 | 0 | 7.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 1.9 | 2 | 5.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 494.8 | -433.3 | -225.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 729.9 | -656.4 | -64.9 | ||||||||||||||||||
cash-flows.row.inventory | 0 | -2.2 | -14 | -2.4 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -232.9 | 237.1 | -158.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -645.9 | -15.2 | 4.2 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -62.9 | -69.8 | -12.2 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 7.5 | -6.5 | 0.5 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -51.8 | -0.5 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0.1 | 4.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -128.4 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -55.4 | -256.3 | -8.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -31.1 | -8.2 | -52.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -3.6 | -3 | -4.3 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | -9.6 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -156 | -270.8 | -210.1 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -149.4 | -282 | -266.6 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2.2 | -2.3 | 0.2 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 114.1 | -57.8 | -234 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 206.9 | 92.8 | 150.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 92.8 | 150.6 | 384.5 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 192.6 | 482.7 | 40.5 | ||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -62.9 | -69.8 | -12.2 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 129.7 | 413 | 28.3 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 212 | 1851.5 | 623.8 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 177.7 | 750.6 | 265.7 | ||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 34.3 | 1101 | 358 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.6 | -3.4 | 0.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 158 | 251.5 | 168.8 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 335.7 | 1002.1 | 434.5 | ||||||||||||||||||
income-statement-row.row.interest-income | 0 | 3.7 | 0.2 | 0 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.3 | 3.5 | 6.5 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -10.7 | 11.1 | -8.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.6 | -3.4 | 0.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -10.7 | 11.1 | -8.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.3 | 3.5 | 6.5 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 55.6 | 58.4 | 68.1 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 0 | -123.7 | 851.7 | 189.4 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -134.3 | 862.8 | 180.7 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1.3 | 157.3 | 48.1 | ||||||||||||||||||
income-statement-row.row.net-income | 0 | -95.4 | 705.6 | 132.6 |
Biežāk uzdotie jautājumi
Kas ir China Biotech Services Holdings Limited (8037.HK) kopējie aktīvi?
China Biotech Services Holdings Limited (8037.HK) kopējie aktīvi ir 662362000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.100.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.200.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -0.535.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.796.
Kāda ir China Biotech Services Holdings Limited (8037.HK) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -95447000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 100396000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 158009000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.